Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a minor revision to the study record. The change updates the metadata or formatting without altering the study data.SummaryDifference0.0%

- Check12 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a minor update to the page's underlying system. No visible changes to study content or layout are expected.SummaryDifference0.0%

- Check19 days agoChange DetectedThe study record received updates indicating new status information and dates, including a new 'Completed' marker, and the previous 'Active, not recruiting' designation was removed, signaling a progression in the trial's status.SummaryDifference0.1%

- Check26 days agoChange DetectedNew quick-access links were added on the study details page, including 'Check who can join', 'Find Contact Information', 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and the version label was updated from v3.5.5 to v3.6.0 with a formatting change from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.2%

- Check34 days agoChange DetectedNew study locations were added: Tampa, Florida, USA; Antofagasta, Chile (1270244); and Seoul Teugbyeolsi, South Korea (03080) with new site contacts Luis Barra (Site 6003) and Sergio Gloger Kojchen (Site 6002). Older site entries and identifiers were removed or updated (e.g., Tampa 33614-2846, Antofagasta 127-0244, Site 6002/6003 references), and the revision label was updated to v3.5.5.SummaryDifference0.6%

- Check49 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, indicating a new version of the page. This represents a minor update to the page's documentation/history rather than substantive changes to the study information.SummaryDifference0.0%

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.